A 3D Bio-Printed-Based Model for Pancreatic Ductal Adenocarcinoma

Overview

Journal Diseases

Date 2024 Sep 27

PMID 39329875

Authors

Claire Godier

Zakaria Baka

Laureline Lamy

Varvara Gribova

Philippe Marchal

Philippe Lavalle

Eric Gaffet

Lina Bezdetnaya

Halima Alem

Affiliations

Soon will be listed here.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a disease with a very poor prognosis, characterized by incidence rates very close to death rates. Despite the efforts of the scientific community, preclinical models that faithfully recreate the PDAC tumor microenvironment remain limited. Currently, the use of 3D bio-printing is an emerging and promising method for the development of cancer tumor models with reproducible heterogeneity and a precisely controlled structure. This study presents the development of a model using the extrusion 3D bio-printing technique. Initially, a model combining pancreatic cancer cells (Panc-1) and cancer-associated fibroblasts (CAFs) encapsulated in a sodium alginate and gelatin-based hydrogel to mimic the metastatic stage of PDAC was developed and comprehensively characterized. Subsequently, efforts were made to vascularize this model. This study demonstrates that the resulting tumors can maintain viability and proliferate, with cells self-organizing into aggregates with a heterogeneous composition. The utilization of 3D bio-printing in creating this tumor model opens avenues for reproducing tumor complexity in the future, offering a versatile platform for improving anti-cancer therapy models.

References

Steinberg E, Orehov N, Tischenko K, Schwob O, Zamir G, Hubert A . Rapid Clearing for High Resolution 3D Imaging of Ex Vivo Pancreatic Cancer Spheroids. Int J Mol Sci. 2020; 21(20). PMC: 7589457. DOI: 10.3390/ijms21207703. View

Nashimoto Y, Hayashi T, Kunita I, Nakamasu A, Torisawa Y, Nakayama M . Integrating perfusable vascular networks with a three-dimensional tissue in a microfluidic device. Integr Biol (Camb). 2017; 9(6):506-518. DOI: 10.1039/c7ib00024c. View

Szucs D, Fekete Z, Guba M, Kemeny L, Jemnitz K, Kis E . Toward better drug development: Three-dimensional bioprinting in toxicological research. Int J Bioprint. 2023; 9(2):663. PMC: 10090537. DOI: 10.18063/ijb.v9i2.663. View

Abadpour S, Aizenshtadt A, Olsen P, Shoji K, Wilson S, Krauss S . Pancreas-on-a-Chip Technology for Transplantation Applications. Curr Diab Rep. 2020; 20(12):72. PMC: 7674381. DOI: 10.1007/s11892-020-01357-1. View

Mizrahi J, Surana R, Valle J, Shroff R . Pancreatic cancer. Lancet. 2020; 395(10242):2008-2020. DOI: 10.1016/S0140-6736(20)30974-0. View

Gu A, Li J, Qiu S, Hao S, Yue Z, Zhai S . Pancreatic cancer environment: from patient-derived models to single-cell omics. Mol Omics. 2024; 20(4):220-233. DOI: 10.1039/d3mo00250k. View

Arslan-Yildiz A, El Assal R, Chen P, Guven S, Inci F, Demirci U . Towards artificial tissue models: past, present, and future of 3D bioprinting. Biofabrication. 2016; 8(1):014103. DOI: 10.1088/1758-5090/8/1/014103. View

Horder H, Guaza Lasheras M, Grummel N, Nadernezhad A, Herbig J, Ergun S . Bioprinting and Differentiation of Adipose-Derived Stromal Cell Spheroids for a 3D Breast Cancer-Adipose Tissue Model. Cells. 2021; 10(4). PMC: 8066030. DOI: 10.3390/cells10040803. View

Ushio J, Kanno A, Ikeda E, Ando K, Nagai H, Miwata T . Pancreatic Ductal Adenocarcinoma: Epidemiology and Risk Factors. Diagnostics (Basel). 2021; 11(3). PMC: 8003883. DOI: 10.3390/diagnostics11030562. View

10.

Quintard C, Tubbs E, Jonsson G, Jiao J, Wang J, Werschler N . A microfluidic platform integrating functional vascularized organoids-on-chip. Nat Commun. 2024; 15(1):1452. PMC: 10873332. DOI: 10.1038/s41467-024-45710-4. View

11.

Ermis M, Falcone N, de Barros N, Mecwan M, Haghniaz R, Choroomi A . Tunable hybrid hydrogels with multicellular spheroids for modeling desmoplastic pancreatic cancer. Bioact Mater. 2023; 25:360-373. PMC: 9984297. DOI: 10.1016/j.bioactmat.2023.02.005. View

12.

Lee H, Kim J, Choi Y, Cho D . Application of Gelatin Bioinks and Cell-Printing Technology to Enhance Cell Delivery Capability for 3D Liver Fibrosis-on-a-Chip Development. ACS Biomater Sci Eng. 2021; 6(4):2469-2477. DOI: 10.1021/acsbiomaterials.9b01735. View

13.

Halbrook C, Lyssiotis C, Pasca di Magliano M, Maitra A . Pancreatic cancer: Advances and challenges. Cell. 2023; 186(8):1729-1754. PMC: 10182830. DOI: 10.1016/j.cell.2023.02.014. View

14.

Kimura H, Sakai Y, Fujii T . Organ/body-on-a-chip based on microfluidic technology for drug discovery. Drug Metab Pharmacokinet. 2017; 33(1):43-48. DOI: 10.1016/j.dmpk.2017.11.003. View

15.

Dardare J, Witz A, Merlin J, Bochnakian A, Toussaint P, Gilson P . Epithelial to Mesenchymal Transition in Patients with Pancreatic Ductal Adenocarcinoma: State-of-the-Art and Therapeutic Opportunities. Pharmaceuticals (Basel). 2021; 14(8). PMC: 8399337. DOI: 10.3390/ph14080740. View

16.

Nurmik M, Ullmann P, Rodriguez F, Haan S, Letellier E . In search of definitions: Cancer-associated fibroblasts and their markers. Int J Cancer. 2019; 146(4):895-905. PMC: 6972582. DOI: 10.1002/ijc.32193. View

17.

Fang L, Liu Y, Qiu J, Wan W . Bioprinting and its Use in Tumor-On-A-Chip Technology for Cancer Drug Screening: A Review. Int J Bioprint. 2022; 8(4):603. PMC: 9668576. DOI: 10.18063/ijb.v8i4.603. View

18.

Heinrich M, M R H Mostafa A, Morton J, Hawinkels L, Prakash J . Translating complexity and heterogeneity of pancreatic tumor: 3D in vitro to in vivo models. Adv Drug Deliv Rev. 2021; 174:265-293. DOI: 10.1016/j.addr.2021.04.018. View

19.

Huang B, Wei X, Chen K, Wang L, Xu M . Bioprinting of hydrogel beads to engineer pancreatic tumor-stroma microtissues for drug screening. Int J Bioprint. 2023; 9(3):676. PMC: 10236328. DOI: 10.18063/ijb.676. View

20.

Hong S, Song J . 3D bioprinted drug-resistant breast cancer spheroids for quantitative in situ evaluation of drug resistance. Acta Biomater. 2021; 138:228-239. DOI: 10.1016/j.actbio.2021.10.031. View